Success Stories: Our Efficient Team Helps an Internal Medicine Resident in Thoracic Oncology from Austria Win NIW Approval in Less Than 5 Months
Client’s Testimonial:
“Having professional support during this process was essential for the success of my case. I highly recommend this firm. I received perfect instructions and timely responses to my questions—the team from NAILG drafted my letters with the information I provided. A series of revisions from my side and their side leveraged the quality of the materials. Finally, having professionals reviewing and organizing the paperwork alleviated the stress and provided a framework that, in my case, helped me balance my daily professional and personal endeavors. Thank you for your hard work and professionalism.”
On March 15th, 2022, we received another EB-2 NIW (National Interest Waiver) approval for an Internal Medicine Resident in the Field of Thoracic Oncology (Approval Notice).
General Field: Thoracic Oncology
Position at the Time of Case Filing: Internal Medicine Resident
Country of Origin: Austria
State of Residence at the Time of Filing: Connecticut
Approval Notice Date: March 15th, 2022
Processing Time: 4 months, 13 days
Case Summary:
Our NIW client from Austria had a Ph.D. in malignant diseases and was considered an expert in the field of thoracic oncology due to his years of contribution to the field both academically and professionally. Since the EB2-NIW category of nonimmigrant visa is for those foreign nationals who can prove the worth of their research for the United States, we found that our Austrian client was the perfect candidate for it.
His proposed endeavor was to continue his research on developing state-of-the-art approaches for identifying biomarkers and therapeutic targets involved in drug resistance in order to improve cancer patients’ survival rates. It was evident that his research is of great importance because it improves the therapies available for treating all forms of cancer, and thoracic cancer in particular, which primarily includes lung cancer and malignant pleural mesothelioma. So, our team rummaged through his CVs, transcripts, certificates, and letters of recommendation to find more relevant information such as the follows:
- His research has resulted in 13 peer-reviewed journal articles (4 of them first-authored) and 16 peer-reviewed abstracts (5 of them first-authored).
- These publications have been cited a total of 102 times according to Google Scholar.
- Furthermore, his study has received funding from 4 international organizations, namely the FWF Austrian Science Fund, the Hungarian National Research, Development, and Innovation Office, the Vienna Fund for Innovative Interdisciplinary Cancer Research, and Boehringer Ingelheim.
- We also attached 2 letters of recommendation obtained by our client at our request to further bolster his claim to the NIW category.
- We also showed that he has pursued research directly related to his proposed endeavor of developing state-of-the-art approaches for identifying biomarkers and therapeutic targets involved in drug resistance for implementation in routine patient care in order to improve cancer patients’ survival rates for 7 years.
- On the other hand, in the absence of his research, Americans suffering from cancer will continue to lack the innovative treatments necessary to improve survival rates.